Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort

2025-07-29 – Press Releases – www.prnewswire.com

NULISAseq CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced a…

Read the full article here.